Fig. 1 · Structure

Documents & Downloads

Benidipine hydrochloride

Cat. No. A11730 CAS 91599-74-5
Benidipine hydrochloride is a long-acting T-type calcium channel blocker, on blood pressure and renal function in hypertensive patients with diabetes mellitus.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Benidipine hydrochloride Research Summary

This section summarizes 4 in vitro studies of Benidipine hydrochloride from 3 published references. In vitro models include U251; Vero cells.

Benidipine hydrochloride In Vitro Studies

Benidipine rescued impaired neurite outgrowth in PARK2-DA neurons following treatment at 10 μM for 6 days. In U251 cells, Benidipine alone stimulated ΔΨm dissipation (1.5-fold). In Vero cells, Benidipine hydrochloride produced a dose-dependent reduction in intracellular HTNV S segment RNA compared with the DMSO vehicle, with an IC50 of 3.063 μM. Benidipine also rescued impaired neurite outgrowth in PARK6-DA neurons following treatment at 10 μM for 6 days. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Benidipine rescues neurite outgrowth in PARK2-derived neurons

Cell-based study · PARK2-derived neurons; n = 4 independent biological replicates [1]

PARK2-derived neurons were treated with benidipine or DMSO. Benidipine rescued impaired neurite outgrowth in PARK2-DA neurons.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Neurite lengthReported result benidipine also rescued impaired neurite outgrowth in PARK2-DA neurons[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
for 6 days
Method
treated with DMSO or benidipine
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Benidipine

The paper names Benidipine without stating the salt or form; not verified as the hydrochloride form supplied as A11730. No dose conversion or lot validation.

Results > A Calcium Channel Antagonist Prevented Rotenone-Induced Apoptosis and Rescued Impaired Neurite Outgrowth in PARK2-Dopaminergic Neurons (S51); Figure 3 legend (S138, S140)

Neurite length: Neurite length; comparator: DMSO — Results > A Calcium Channel Antagonist Prevented Rotenone-Induced Apoptosis and Rescued Impaired Neurite Outgrowth in PARK2-Dopaminergic Neurons (S51); Figure 3 legend (S138)

In U251, benidipine alone stimulated ∆Ψm dissipation

Cell-based study · U251 [2]

U251 cells were treated with Benidipine at 1 µM. Benidipine alone stimulated ΔΨm dissipation (1.5-fold).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
normalized percentage of U251 cells with dissipated ΔΨm∆Ψm dissipation 1.5-fold[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 µM
Exposure duration
5–7 days
Vehicle
0.1% DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Benidipine

The paper names Benidipine without stating the salt or form; not verified as the hydrochloride form supplied as A11730. No dose conversion or lot validation.

2. Materials and Methods > 2.6. Determination of Inner Mitochondrial Membrane Potential (ΔΨm) (S24); 3. Results (S92, S95); Figure 8 legend (S167)

normalized percentage of U251 cells with dissipated ΔΨm: normalized percentage of U251 cells with dissipated ΔΨm; comparator: vehicle/control — 3. Results (S95); Figure 8 legend (S167)

Benidipine reduces intracellular HTNV S segment RNA

Cell-based study · Vero cells [3]

Vero cells received Benidipine hydrochloride during and after virus adsorption. Compared with the DMSO vehicle, treatment produced a dose-dependent reduction in intracellular HTNV S segment RNA, with an IC50 of 3.063 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
relative intracellular RNA levels of the HTNV S segmentIC50 IC50 of 3.063 μM[3]

Literature-Reported Treatment Conditions

Exposure duration
1 hour prior to HTNV infection
Method
added during and after virus adsorption
Vehicle
DMSO
Co-treatment
Other interventions in this design: HTNV MOI) of 1. Compound effect isolated by the comparison: in comparison with the DMSO vehicle.
Reported limits
Not stated in the sentences used: dose.
Methods and source locations

Compound reported in the paper: Benidipine hydrochloride; Compound label in the paper: BENIDIPINE

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Benidipine hydrochloride inhibits Hantaan virus infection in different cell lines (S44, S45, S46)

relative intracellular RNA levels of the HTNV S segment: relative intracellular RNA levels of the HTNV S segment; comparator: DMSO vehicle — Results > Benidipine hydrochloride inhibits Hantaan virus infection in different cell lines (S45, S46)

Benidipine rescues neurite outgrowth in PARK6-DA neurons

Cell-based study · PARK6-DA neurons; n = 4 independent biological replicates [1]

PARK6-DA neurons were treated with benidipine or DMSO. Benidipine rescued impaired neurite outgrowth.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Neurite lengthReported result rescued impaired neurite outgrowth[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
for 6 days
Method
treated with DMSO or benidipine
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Benidipine

The paper names Benidipine without stating the salt or form; not verified as the hydrochloride form supplied as A11730. No dose conversion or lot validation.

Results > A Calcium Channel Antagonist Displayed Neuroprotective Effects against Dopaminergic Neurons Derived from a PARK6 Patient-Specific iPSC Line (S61); Figure 4 legend (S149, S150)

Neurite length: Neurite length; comparator: DMSO — Results > A Calcium Channel Antagonist Displayed Neuroprotective Effects against Dopaminergic Neurons Derived from a PARK6 Patient-Specific iPSC Line (S61); Figure 4 legend (S149)

Specifications

Manufacturer Adooq Bioscience
Actions Blocker
CAS Number 91599-74-5
Formula C28H31N3O6.HCl
Molecular Weight 542.02
SMILES
CC1=C([C@H](C(=C(N1)C)C(=O)O[C@@H]2CCCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 7 mg/mL (12.91 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Benidipine hydrochloride Research References

  1. [1] Tabata Y, Imaizumi Y, Sugawara M, et al. T-type Calcium Channels Determine the Vulnerability of Dopaminergic Neurons to Mitochondrial Stress in Familial Parkinson Disease. Stem Cell Reports (2018). PMID: 30344006 DOI: 10.1016/j.stemcr.2018.09.006 Source material
  2. [2] Neuhaus E, Zirjacks L, Ganser K, et al. Alternating Electric Fields (TTFields) Activate Cav1.2 Channels in Human Glioblastoma Cells. Cancers (Basel) (2019). PMID: 30669316 DOI: 10.3390/cancers11010110 Source material
  3. [3] Wang B, Pei J, Zhang H, et al. Dihydropyridine-derived calcium channel blocker as a promising anti-hantavirus entry inhibitor. Front Pharmacol (2022). PMID: 36105208 DOI: 10.3389/fphar.2022.940178 Source material

Added to your cart

View Cart Checkout
Loading...